All articles tagged with #medical trial
A man initially thought to have terminal lung cancer was finally diagnosed with a rare immune condition called IgG4-RD after a year of misdiagnosis, leading to a groundbreaking treatment trial that significantly improved his health and inspired advocacy efforts.
A French anesthetist, Frederic Pechier, is set to go on trial for allegedly poisoning 30 patients, resulting in 12 deaths, in an attempt to showcase his resuscitation skills and discredit colleagues. The case, spanning seven years and involving suspicious cardiac arrests, is considered unprecedented in France and highlights concerns about medical misconduct. Pechier denies the charges and faces life imprisonment if convicted.
A Pittsburgh-based biotech company is conducting a groundbreaking trial to grow a "mini liver" from a patient's own lymph node, aiming to provide a life-saving therapy for those in need of liver transplants. The trial, currently in progress with one patient suffering from end-stage liver disease, seeks to test the efficacy of the company's regenerative cell therapy.
An 80-year-old man who participated in a medical trial for the Alzheimer's drug donanemab gained confidence and was able to sing at his 80th birthday party. Donanemab, created by Eli Lilly, has been found to slow cognitive and functional decline in patients with early-stage Alzheimer's by 35% over 18 months. The drug targets a protein called amyloid that builds up in the brains of Alzheimer's patients. Eli Lilly has submitted the drug for FDA approval.
An 80-year-old man participating in a medical trial for the Alzheimer's drug donanemab reported gaining confidence and improved cognitive abilities, including the ability to sing in front of a crowd. Donanemab, developed by Eli Lilly, has shown promising results in slowing cognitive and functional decline in patients with early-stage Alzheimer's. The drug targets the amyloid protein that builds up in the brains of Alzheimer's patients. While the drug has shown positive effects, it also carries the risk of brain swelling as a side effect. Eli Lilly has submitted donanemab for FDA approval and expects updates by the end of the year.